HomeInsightsStock Comparison

Biocon Ltd vs Zydus Lifesciences Ltd Stock Comparison

Biocon Ltd vs Zydus Lifesciences Ltd Stock Comparison

Last Updated on: Jun 27, 2025

Key Highlights

  • The Latest Trading Price of Biocon Ltd is ₹ 350.6 as of 27 Jun 09:12.
  • The P/E Ratio of Biocon Ltd changed from 43.4 on March 2020 to 31 on March 2024 . This represents a CAGR of -6.51% over 5 yearsThe P/E Ratio of Zydus Lifesciences Ltd changed from 23.3 on March 2020 to 26.2 on March 2024 . This represents a CAGR of 2.37% over 5 years.
  • The Market Cap of Biocon Ltd changed from ₹ 32472 crore on March 2020 to ₹ 31707 crore on March 2024 . This represents a CAGR of -0.48% over 5 yearsThe Market Cap of Zydus Lifesciences Ltd changed from ₹ 27344 crore on March 2020 to ₹ 101151 crore on March 2024 . This represents a CAGR of 29.90% over 5 years.
  • The revenue of Biocon Ltd for the Mar '25 is ₹ 4474 crore as compare to the Dec '24 revenue of ₹ 3874 crore. This represent the growth of 15.49% The revenue of Zydus Lifesciences Ltd for the Mar '25 is ₹ 6608 crore as compare to the Dec '24 revenue of ₹ 5326 crore. This represent the growth of 24.07%.
  • The ebitda of Biocon Ltd for the Mar '25 is ₹ 1135 crore as compare to the Dec '24 ebitda of ₹ 804.7 crore. This represent the growth of 41.11% The ebitda of Zydus Lifesciences Ltd for the Mar '25 is ₹ 1986 crore as compare to the Dec '24 ebitda of ₹ 1444 crore. This represent the growth of 37.49%.
  • The net profit of Biocon Ltd changed from ₹ 148.9 crore to ₹ 459.4 crore over 8 quarters. This represents a CAGR of 75.65% The net profit of Zydus Lifesciences Ltd changed from ₹ 1112 crore to ₹ 1248 crore over 8 quarters. This represents a CAGR of 5.97% .
  • The Dividend Payout of Biocon Ltd changed from 69.72 % on March 2022 to 50.32 % on March 2024 . This represents a CAGR of -10.30% over 3 yearsThe Dividend Payout of Zydus Lifesciences Ltd changed from 25.37 % on March 2020 to 8.77 % on March 2024 . This represents a CAGR of -19.14% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Biocon Ltd

  • Biocon Limited is India's largest and fully-integrated, innovation-led biopharmaceutical company.
  • Biocon, with its key business verticals of Generics, Biosimilars, Research Services and Novel Biologics, has leveraged its affordable innovation model and scientific capabilities to develop and manufacture both small and large molecules at global scale for the benefit of patients.
  • At present, Company is engaged in the manufacture of biotechnology products and research services. Biocon Limited was incorporated in year 1978 as a joint venture between Biocon Biochemicals Limited of Ireland and an Indian entrepreneur, Kiran Mazumdar-Shaw.
  • Biocon manufactured and exported enzymes to USA and Europe during the year 1979, as first of its kind.
  • In 1989, Unilever plc acquired the Biocon Biochemicals Limited in Ireland and merges it with its subsidiary, Quest International.

About Zydus Lifesciences Ltd

  • Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited) is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products.
  • The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh. Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996.

Biocon Ltd News Hub

News

Biocon raises Rs 4,500 crore via QIP

Biocon has successfully concluded a Qualified Institutions Placement (QIP), raising Rs 4,5...

Read more

21 Jun 2025 09:13

News

Biocon get facilities rated

CRISIL Ratings Limited has re-affirmed the Long Term rating of Biocon at CRISIL AA+/Stable...

Read more

18 Jun 2025 09:41

News

Biocon Ltd soars 3.52%, Gains for third straight session

Biocon Ltd is up for a third straight session in a row. The stock is quoting at Rs 353.2, ...

Read more

11 Jun 2025 13:05

News

Biocon gets CDSCO approval for Liraglutide drug substance

Additionally, its wholly owned subsidiary, Biocon Pharma, has received CDSCO approval for ...

Read more

03 Jun 2025 08:23

News

Biocon Ltd spurts 1.3%, up for five straight sessions

Biocon Ltd rose for a fifth straight session today. The stock is quoting at Rs 343.8, up 1...

Read more

19 May 2025 13:00

News

Biocon's subsidiary get US FDA nod for anticoagulant medication Rivaroxaban

Rivaroxaban is a prescription medication used in the treatment of deep vein thrombosis and...

Read more

16 May 2025 09:38

Zydus Lifesciences Ltd News Hub

News

Zydus Life Matoda facility receives two observations from USFDA after inspection

In a regulatory filing, the company confirmed that the USFDA conducted a follow-up inspect...

Read more

19 Jun 2025 09:50

News

Zydus Lifesciences appoints Managing Director

Zydus Lifesciences has approved the appointment of s. Swati Dalal as the Additional Direct...

Read more

16 Jun 2025 14:16

News

Zydus Life subsidiary ZHL appoints Swati Dalal as MD

The appointment was approved by the nomination and remuneration committee (NRC). Swati Dal...

Read more

16 Jun 2025 14:42

News

Zydus Life receives USFDA EIR for Gujarat facility

The inspection was conducted by the USFDA from March 10 to March 14, 2025. Following the r...

Read more

12 Jun 2025 09:55

News

Zydus' Ankleshwar API unit clears USFDA inspection

Zydus Lifesciences has received the Establishment Inspection Report (EIR) report from the ...

Read more

12 Jun 2025 10:41

News

Zydus Lifesciences Ltd spurts 0.24%, up for fifth straight session

Zydus Lifesciences Ltd is up for a fifth straight session today. The stock is quoting at R...

Read more

10 Jun 2025 13:00

SWOT Analysis Of Biocon Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Zydus Lifesciences Ltd

Strength

3

S

Weakness

3

W

Opportunity

0

O

Threats

2

T

BlinkX Score for Biocon Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Zydus Lifesciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Biocon Ltd and Zydus Lifesciences Ltd

Which company has a larger market capitalization, Biocon Ltd or Zydus Lifesciences Ltd?

Market cap of Biocon Ltd is 46,867 Cr while Market cap of Zydus Lifesciences Ltd is 98,822 Cr

What are the key factors driving the stock performance of Biocon Ltd and Zydus Lifesciences Ltd?

The stock performance of Biocon Ltd and Zydus Lifesciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Biocon Ltd and Zydus Lifesciences Ltd?

As of June 27, 2025, the Biocon Ltd stock price is INR ₹350.55. On the other hand, Zydus Lifesciences Ltd stock price is INR ₹982.1.

How do dividend payouts of Biocon Ltd and Zydus Lifesciences Ltd compare?

To compare the dividend payouts of Biocon Ltd and Zydus Lifesciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions